



(12) Translation of new
European patent specification
After limitation procedure

(11) NO/EP 3106463 B3

NORWAY

(19) NO
(51) Int Cl.

C07D 471/04 (2006.01)
A61K 31/519 (2006.01)
A61P 29/00 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2018.07.16
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.02.28
(45)	Decision of the opposition in EPO	2020.01.22
	Decision of the opposition in NIPO	2020.04.27
(86)	European Application Nr.	16166461.0
(86)	European Filing Date	2009.10.21
(87)	The European Application's Publication Date	2016.12.21
(30)	Priority	2008.10.22, US, 107616 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	AL ; BA ; RS
(73)	Proprietor	Array Biopharma, Inc., 3200 Walnut Street, Boulder, CO 80301, USA
(72)	Inventor	HAAS, Julia, C/O Array Biopharma Inc.3200 Walnut Street, Boulder, CO 80301, USA ANDREWS, Steven, W., C/O Array Biopharma Inc.3200 Walnut Street, Boulder, CO 80301, USA JIANG, Yutong, C/O Array Biopharma Inc.3200 Walnut Street, Boulder, CO 80301, USA ZHANG, Gan, C/O Array Biopharma Inc.3200 Walnut Street, Boulder, CO 80301, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	PYRAZOLO[1,5-]PYRIMIDINE COMPOUND AS TRK KINASE INHIBITOR
(56)	References Cited:	WO-A1-2006/115452 WO-A1-2006/087538

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

EP3106463


1

Patentkrav**1.** Forbindelse som er:

5 (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-karboksamid; eller et farmasøytisk akseptabelt salt derav.

2. Forbindelsen ifølge krav 1, hvori forbindelsen er et trifluoracetatsalt, et hydrogensulfatsalt eller et hydrokloridsalt.

10

3. Forbindelsen ifølge krav 1, hvori forbindelsen er:

(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-karboksamidsulfat.

15

4. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1 til 3 og en farmasøytisk akseptabel fortynner eller bærer.